3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Paclitaxel
42
Carboplatin
35
pembrolizumab
25
Surveys and Questionnaires
23
Letrozole
15
Radiotherapy
14
Megestrol Acetate
14
Blood Specimen Collection
14
Bevacizumab
13
olaparib
12
Metformin
12
dostarlimab
10
Indocyanine Green
10
durvalumab
9
Observation
9
Medroxyprogesterone Acetate
9
Cisplatin
9
lenvatinib
8
atezolizumab
8
Early Intervention, Educational
8
Counseling
8
niraparib
7
Sentinel Lymph Node Biopsy
7
Radiation
7
Methods
7
Magnetic Resonance Spectroscopy
7
Lymph Node Excision
7
Hysterectomy
7
Everolimus
7
abemaciclib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Endometrial Neoplasms
×
nanocis
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled